Stay updated on SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial

Sign up to get notified when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    An NIH announcement banner was added, linking to updates about the transition from “Artificial Intelligence” to “Super Intelligence” terminology across NIH content.
    Difference
    1%
    Check dated 2026-10-25T12:15:30.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-18T11:39:26.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T14:06:48.000Z thumbnail image
  4. Check
    42 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of the study details, indicating access to the study information is blocked for the current user. This appears to be an access/permissions issue rather than a substantive update to the study content.
    Difference
    20%
    Check dated 2026-09-20T20:23:58.000Z thumbnail image
  5. Check
    63 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.6.6, replacing the previous Revision: v3.6.5. This appears to be a minor version update and does not modify the study content or details presented on the page.
    Difference
    0.1%
    Check dated 2026-08-30T21:57:59.000Z thumbnail image
  6. Check
    84 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.4 to v3.6.5 on the page metadata. This indicates an internal update to the page’s version, with no visible changes to the study details or user-facing content.
    Difference
    0.0%
    Check dated 2026-08-09T08:42:43.000Z thumbnail image

Stay in the know with updates to SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.